PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

PROCEPT BioRobotics Corporation

PROCEPT BioRobotics develops and manufactures the AquaBeam Robotic System for aquablation therapy, a treatment for benign prostatic hyperplasia (BPH).

PROCEPT BioRobotics

PROCEPT BioRobotics is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. Our proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience.

Armentum Partners

CIBC Innovation Banking

Novo Holdings

Perceptive Advisors

Viking Global Investors

CPMG

T. Rowe Price

Duquesne Family Office

Fidelity

Fidelity Management and Research Company

Say hello to Barry Templin, a rockstar on our executive leadership team! With over 20 years of experience in clinical research, engineering, and market development, Barry’s expertise is transforming patient care.

From leading the game-changing PROSPECT study at Abbott Vascular to driving innovation at CardioKinetix, Barry’s journey has been nothing short of impressive. He started in engineering at GE Aircraft Engines and Guidant, and then transitioned to key clinical roles at Guidant and Abbott.

Barry holds a BS in Mechanical Engineering from Rose-Hulman Institute of Technology, and an MBA from Duke. 

We’re lucky to have Barry’s talent and passion fueling our mission to innovate and improve lives.

#Leadership #MedicalDevices

When Ed began experiencing #BPH symptoms, he was told, "Welcome to the club," but had no desire to be a part of it. 

Thanks to #Aquablation therapy, he experienced immediate and lasting symptom relief. https://bit.ly/3tFJM6X

Not all patients will experience the same results

Aquablation therapy now has 5-year results from two pivotal studies that demonstrate the reproducibility of Aquablation therapy to deliver significant symptom relief while preserving sexual function no matter the size of the patient’s prostate,” said Sham Shiblaq, EVP and Chief Commercial Officer of PROCEPT BioRobotics.
These impressive results are further validated by the growing number of hospitals and surgeons adopting Aquablation as their new standard of care for BPH treatment. Discover the advantages of #AquablationTherapy for managing #BPH patients. Explore the Five-Year data from the WATER II study: https://lnkd.in/dFBwzBfJ
#ClinicalStudy #BPHTreatment

Ever wondered why your fellow urologists are raving about Aquablation therapy? 
Catch Episode 103 of the Prostate Health Podcast! Dr. Jennifer E. Lloyd-Harris dives deep into why she chose to adopt this groundbreaking robotic waterjet technology in her practice. 
Discover what makes Aquablation therapy a game-changer for BPH treatment and why you should consider offering it to your patients.
#ProstateHealthPodcast #AquablationTherapy 
https://bit.ly/4cCXzN0

Ever wondered what’s going on with your plumbing? A normal prostate lets urine flow smoothly, but an enlarged prostate can turn that into a tricky business. 
Think of benign prostatic hyperplasia (BPH) as a friendly but overgrown neighbor—it’s not cancer, but it can cause some serious blockages! Left unchecked, it might lead to bladder or kidney issues.
#ProstateHealth #BPH

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-41.98M -	-53.02M 26.31%	-59.85M 12.89%	-87.15M 45.61%	-105.90M 21.51%
depreciation and amortization	1.49M -	2.86M 91.43%	3.32M 16.22%	2.84M 14.53%	3.81M 34.00%
deferred income tax		223K -	451K 102.24%		26.32M -
stock based compensation	1.99M -	2.17M 8.98%	3.80M 74.69%	10.34M 172.31%	19.13M 85.10%
change in working capital	-3.53M -	-483K 86.33%	-4.71M 874.53%	-11.49M 144.04%	-26.16M 127.75%
accounts receivables	522K -	-511K 197.89%	-2.91M 470.25%	-10.81M 270.93%	-33.10M 206.25%
inventory	-5.07M -	-3.10M 38.81%	-6.12M 97.23%	-15.25M 149.04%	-9.75M 36.06%
accounts payables	-260K -	-205K 21.15%	812K 496.10%	3.96M 387.56%	5.79M 46.22%
other working capital	1.28M -	3.34M 160.78%	3.52M 5.42%	10.61M 201.62%	10.90M 2.72%
other non cash items	-1.80M -	-97K 94.61%	-345K 255.67%	5.08M 1,572.75%	-25.20M 596.04%
net cash provided by operating activities	-43.82M -	-48.34M 10.33%	-57.33M 18.60%	-80.38M 40.20%	-108.00M 34.36%
investments in property plant and equipment	-7.61M -	-233K 96.94%	-592K 154.08%	-2.65M 348.14%	-25.21M 850.09%
acquisitions net
purchases of investments
sales maturities of investments	50.76M -
other investing activites
net cash used for investing activites	43.15M -	-233K 100.54%	-592K 154.08%	-2.65M 348.14%	-25.21M 850.09%
debt repayment	-24.53M -	-24.68M 0.62%		-53M -
common stock issued	1.99M -	82.09M 4,016.65%	172.36M 109.98%	4.01M 97.67%	167.79M 4,086.50%
common stock repurchased				2.41M -	3.61M 49.85%
dividends paid
other financing activites	49.07M -	49.37M 0.62%	89.75M 81.79%	50.20M 44.07%	-3.61M 107.19%
net cash used provided by financing activities	26.53M -	106.77M 302.50%	262.12M 145.49%	3.61M 98.62%	167.79M 4,545.49%
effect of forex changes on cash					-1 -
net change in cash	25.86M -	58.20M 125.02%	204.19M 250.87%	-79.42M 138.90%	34.59M 143.55%
cash at beginning of period	16.85M -	42.71M 153.48%	100.91M 136.25%	305.10M 202.35%	222.64M 27.03%
cash at end of period	42.71M -	100.91M 136.25%	305.10M 202.35%	225.67M 26.03%	257.22M 13.98%
operating cash flow	-43.82M -	-48.34M 10.33%	-57.33M 18.60%	-80.38M 40.20%	-108.00M 34.36%
capital expenditure	-7.61M -	-233K 96.94%	-592K 154.08%	-2.65M 348.14%	-25.21M 850.09%
free cash flow	-51.43M -	-48.58M 5.55%	-57.93M 19.25%	-83.03M 43.35%	-133.21M 60.43%

COM:PROCEPT-BIOROBOTICS

PROCEPT BioRobotics

Last Close

94.45

22/11 21:00

Market Cap

3.35B

Beta: -

Volume Today

361.21K

Avg: -

Preview